Literature DB >> 33368017

Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild Cognitive Impairment: A Narrative Review.

Barry S Baumel1, P Murali Doraiswamy2, Marwan Sabbagh3, Richard Wurtman4.   

Abstract

In mild cognitive impairment (MCI) due to Alzheimer disease (AD), also known as prodromal AD, there is evidence for a pathologic shortage of uridine, choline, and docosahexaenoic acid [DHA]), which are key nutrients needed by the brain. Preclinical and clinical evidence shows the importance of nutrient bioavailability to support the development and maintenance of brain structure and function in MCI and AD. Availability of key nutrients is limited in MCI, creating a distinct nutritional need for uridine, choline, and DHA. Evidence suggests that metabolic derangements associated with ageing and disease-related pathology can affect the body's ability to generate and utilize nutrients. This is reflected in lower levels of nutrients measured in the plasma and brains of individuals with MCI and AD dementia, and progressive loss of cognitive performance. The uridine shortage cannot be corrected by normal diet, making uridine a conditionally essential nutrient in affected individuals. It is also challenging to correct the choline shortfall through diet alone, because brain uptake from the plasma significantly decreases with ageing. There is no strong evidence to support the use of single-agent supplements in the management of MCI due to AD. As uridine and choline work synergistically with DHA to increase phosphatidylcholine formation, there is a compelling rationale to combine these nutrients. A multinutrient enriched with uridine, choline, and DHA developed to support brain function has been evaluated in randomized controlled trials covering a spectrum of dementia from MCI to moderate AD. A randomized controlled trial in subjects with prodromal AD showed that multinutrient intervention slowed brain atrophy and improved some measures of cognition. Based on the available clinical evidence, nutritional intervention should be considered as a part of the approach to the management of individuals with MCI due to AD, including adherence to a healthy, balanced diet, and consideration of evidence-based multinutrient supplements.

Entities:  

Keywords:  Alzheimer disease; Choline; Docosahexaenoic acid; Mild cognitive impairment; Multinutrient; Uridine

Year:  2020        PMID: 33368017     DOI: 10.1007/s40120-020-00227-y

Source DB:  PubMed          Journal:  Neurol Ther        ISSN: 2193-6536


  129 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 3.  Neuro-regeneration Therapeutic for Alzheimer's Dementia: Perspectives on Neurotrophic Activity.

Authors:  Miao-Kun Sun; Daniel L Alkon
Journal:  Trends Pharmacol Sci       Date:  2019-08-08       Impact factor: 14.819

4.  Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Authors:  Ronald C Petersen; Oscar Lopez; Melissa J Armstrong; Thomas S D Getchius; Mary Ganguli; David Gloss; Gary S Gronseth; Daniel Marson; Tamara Pringsheim; Gregory S Day; Mark Sager; James Stevens; Alexander Rae-Grant
Journal:  Neurology       Date:  2017-12-27       Impact factor: 9.910

Review 5.  The road to restoring neural circuits for the treatment of Alzheimer's disease.

Authors:  Rebecca G Canter; Jay Penney; Li-Huei Tsai
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

Review 6.  The diagnosis and management of mild cognitive impairment: a clinical review.

Authors:  Kenneth M Langa; Deborah A Levine
Journal:  JAMA       Date:  2014-12-17       Impact factor: 56.272

7.  Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability.

Authors:  Martijn C de Wilde; Cassia R Overk; John W Sijben; Eliezer Masliah
Journal:  Alzheimers Dement       Date:  2016-01-14       Impact factor: 21.566

Review 8.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Steven T Dekosky; Pascale Barberger-Gateau; Jeffrey Cummings; André Delacourte; Douglas Galasko; Serge Gauthier; Gregory Jicha; Kenichi Meguro; John O'brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Yaakov Stern; Pieter J Visser; Philip Scheltens
Journal:  Lancet Neurol       Date:  2007-08       Impact factor: 44.182

Review 9.  Dementia prevention, intervention, and care.

Authors:  Gill Livingston; Andrew Sommerlad; Vasiliki Orgeta; Sergi G Costafreda; Jonathan Huntley; David Ames; Clive Ballard; Sube Banerjee; Alistair Burns; Jiska Cohen-Mansfield; Claudia Cooper; Nick Fox; Laura N Gitlin; Robert Howard; Helen C Kales; Eric B Larson; Karen Ritchie; Kenneth Rockwood; Elizabeth L Sampson; Quincy Samus; Lon S Schneider; Geir Selbæk; Linda Teri; Naaheed Mukadam
Journal:  Lancet       Date:  2017-07-20       Impact factor: 202.731

Review 10.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.

Authors:  Gill Livingston; Jonathan Huntley; Andrew Sommerlad; David Ames; Clive Ballard; Sube Banerjee; Carol Brayne; Alistair Burns; Jiska Cohen-Mansfield; Claudia Cooper; Sergi G Costafreda; Amit Dias; Nick Fox; Laura N Gitlin; Robert Howard; Helen C Kales; Mika Kivimäki; Eric B Larson; Adesola Ogunniyi; Vasiliki Orgeta; Karen Ritchie; Kenneth Rockwood; Elizabeth L Sampson; Quincy Samus; Lon S Schneider; Geir Selbæk; Linda Teri; Naaheed Mukadam
Journal:  Lancet       Date:  2020-07-30       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.